PALO ALTO, Calif., March 25, 2022 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex”), a majority-owned…
Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people…
CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response…
Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial Randomization phase of…
Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single…
BASEL, Switzerland, March 25, 2022 (GLOBE NEWSWIRE) — Noema Pharma, a Swiss-based clinical-stage company targeting…
Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life…
MORF-057, an oral α4β7 integrin inhibitor candidate, holds potential for treating inflammatory bowel diseases Phase…
– Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than…
Sub-analysis of the Phase 2b CONTROL study in congenital ichthyosis demonstrates treatment success with TMB-001…
Virtual Bio-Europe Spring 2022 Kempen Life Sciences Conference Asebio Investor Day MADRID, Spain and CAMBRIDGE,…
New 3-D process designed to increase yield and improve operating efficiency for rapid and scalable…
Pooled analysis of DERMIS-1 and DERMIS-2 demonstrated significantly more roflumilast-treated patients achieved Investigator Global Assessment…
Previously reported data demonstrated that roflumilast foam provided statistically significant improvement in disease severity and…
LAVAL, Quebec, March 25, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”)…
Reached new record market share overall adult use market share of 2.06% in February 2022,…
Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis (AD) underway with topline data…
OXFORD, United Kingdom, March 25, 2022 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC) today announced…
Approval of 36-month shelf life encompasses all ASCENIV & BIVIGAM vial sizes, production scales, as…
BALA CYNWYD, Pa., March 25, 2022 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR),…